Eaton’s Vehicle Group Launches Electric Vehicle E-Drive Gearing Design, Development and Manufacturing
18.2.2021 14:30:00 EET | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group is developing gearing solutions for electrified vehicles (EVs). Leveraging its expertise in producing transmissions and contract manufactured gear-sets for passenger and commercial vehicles, the Vehicle Group aims to be a leader in the global design, development and supply of EV reduction gearing. The new technology complements Eaton’s eMobility power electronics portfolio in the electrified vehicle powertrain market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210218005131/en/
Eaton’s Vehicle Group can partner with customers on joint-development programs or serve as a single service provider of EV reduction gearing components or systems. (Photo: Business Wire)
Eaton meets electrified vehicle challenges
Automakers face many challenges when developing an electrified vehicle, such as optimizing efficiency, weight, noise, vibration and harshness (NVH), and dealing with packaging constraints. Eaton can help manufacturers meet these challenges by applying its many years of experience and in-house capability in design, validation and manufacturing of high-precision, high-quality gearing systems for transmissions and powertrains.
“We are partnering with OEM customers to leverage our expertise in simulation, design and manufacturing to optimize the efficiency, NVH and weight of high-precision gearing systems tailored to specific customer needs,” said Anthony Cronin, director, EV gearing, Eaton’s Vehicle Group.
Whether a large-scale industrialization project or a niche-market application, Eaton can partner with customers on joint-development programs or serve as a single service provider of EV reduction gearing components or systems. Eaton’s expertise in both design and manufacturing allows us to optimize solutions from a technical, commercial and production aspect, reducing the risk of multi-iteration design and enabling shortened development times.
Eaton transmission experience drives efficiency
Eaton conducts a total system analysis, using state-of-the-art tools and in-house expertise, to design EV gearing solutions that are optimized for efficiency and reliability, with low noise and manufacturing costs. A full-system approach is essential when tailoring a design to a specific customer need, as several factors influence the development of gearing solutions. Chief among those factors are the gears, bearings and lubrication system. To achieve optimization in these three areas, Eaton applies a series of in-house design and manufacturing techniques, including:
- Gear root geometry optimization for maximum strength.
- Micro and macro gear geometry modelling to improve NVH, efficiency and reliability.
- Thrust load and bearing loss minimization to improve reliability and simplify or downsize bearings.
- Simulation and selection of lubrication solutions for full-system reliability and efficiency.
Optimized transmission lowers development costs
Eaton engineers evaluate existing layouts or develop “clean-sheet” solutions that work within a customer’s packaging constraint. The Eaton team also provides solutions for scaling the EV gearing layout for platforms with multiple torque requirements.
By combining system design expertise and manufacturing know-how in high-quality precision gears, Eaton has identified opportunities to improve gearing system efficiency by up to 1 percent, reduce weight by up to 20 percent and size by up to 10 percent. These benefits can be applied to both light-duty and commercial electrified vehicles.
Additionally, by applying its manufacturing expertise, including power honing, power skiving, grinding and superfinishing, Eaton can manage the relative production cost of high-quality precision gears. With electrified vehicles, even small efficiency improvements provide vehicle manufacturers new opportunities to manage vehicle range or improve cost and weight.
“The development of EVs is pushing the boundaries of EV gearing. Reliable, efficient and quiet gearing systems are critical to high-speed motor adoption in electric drives,” said Cronin.
Learn more about Eaton’s Vehicle Group EV Gearing solutions.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 92,000 employees. For more information, visit www.eaton.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005131/en/
Contact information
Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom